The establishment of a multiple myeloma clinical registry in the Asia–Pacific region: The Asia–Pacific Myeloma and Related Diseases Registry (APAC MRDR)
Multiple myeloma (MM) is the second most common haematological cancer worldwide. Along with related diseases including monoclonal gammopathy of undetermined significance (MGUS), plasma cell leukaemia (PCL) and plasmacytoma, MM incidence is rising, yet it remains incurable and represents a significan...
Saved in:
| Published in | BMC medical research methodology Vol. 24; no. 1; pp. 102 - 11 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
BioMed Central Ltd
02.05.2024
BioMed Central BMC |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Multiple myeloma (MM) is the second most common haematological cancer worldwide. Along with related diseases including monoclonal gammopathy of undetermined significance (MGUS), plasma cell leukaemia (PCL) and plasmacytoma, MM incidence is rising, yet it remains incurable and represents a significant disease burden. Clinical registries can provide important information on management and outcomes, and are vital platforms for clinical trials and other research. The Asia-Pacific Myeloma and Related Diseases Registry (APAC MRDR) was developed to monitor and explore variation in epidemiology, treatment regimens and their impact on clinical outcomes across this region. Here we describe the registry's design and development, initial data, progress and future plans.
The APAC MRDR was established in 2018 as a multicentre collaboration across the Asia-Pacific, collecting prospective data on patients newly diagnosed with MM, MGUS, PCL and plasmacytoma in Korea, Singapore, Malaysia and Taiwan, with China recently joining. Development of the registry required a multidisciplinary team of clinicians, researchers, legal and information technology support, and financial resources, as well as local clinical context from key opinion leaders in the APAC region. Written informed consent is obtained and data are routinely collected throughout treatment by hospital staff. Data are stored securely, meeting all local privacy and ethics requirements. Data were collected from October 2018 to March 2024.
Over 1700 patients from 24 hospitals have been enrolled onto the APAC MRDR to date, with the majority (86%) being newly diagnosed with MM. Bortezomib with an immunomodulatory drug was most frequently used in first-line MM therapy, and lenalidomide-based therapy was most common in second-line. Establishment and implementation challenges include regulatory and a range of operational issues.
The APAC MRDR is providing 'real-world' data to participating sites, clinicians and policy-makers to explore factors influencing outcomes and survival, and to support high quality studies. It is already a valuable resource that will continue to grow and support research and clinical collaboration in MM and related diseases across the APAC region. |
|---|---|
| AbstractList | Abstract Background Multiple myeloma (MM) is the second most common haematological cancer worldwide. Along with related diseases including monoclonal gammopathy of undetermined significance (MGUS), plasma cell leukaemia (PCL) and plasmacytoma, MM incidence is rising, yet it remains incurable and represents a significant disease burden. Clinical registries can provide important information on management and outcomes, and are vital platforms for clinical trials and other research. The Asia–Pacific Myeloma and Related Diseases Registry (APAC MRDR) was developed to monitor and explore variation in epidemiology, treatment regimens and their impact on clinical outcomes across this region. Here we describe the registry’s design and development, initial data, progress and future plans. Methods The APAC MRDR was established in 2018 as a multicentre collaboration across the Asia–Pacific, collecting prospective data on patients newly diagnosed with MM, MGUS, PCL and plasmacytoma in Korea, Singapore, Malaysia and Taiwan, with China recently joining. Development of the registry required a multidisciplinary team of clinicians, researchers, legal and information technology support, and financial resources, as well as local clinical context from key opinion leaders in the APAC region. Written informed consent is obtained and data are routinely collected throughout treatment by hospital staff. Data are stored securely, meeting all local privacy and ethics requirements. Data were collected from October 2018 to March 2024. Results Over 1700 patients from 24 hospitals have been enrolled onto the APAC MRDR to date, with the majority (86%) being newly diagnosed with MM. Bortezomib with an immunomodulatory drug was most frequently used in first-line MM therapy, and lenalidomide-based therapy was most common in second-line. Establishment and implementation challenges include regulatory and a range of operational issues. Conclusion The APAC MRDR is providing ‘real-world’ data to participating sites, clinicians and policy-makers to explore factors influencing outcomes and survival, and to support high quality studies. It is already a valuable resource that will continue to grow and support research and clinical collaboration in MM and related diseases across the APAC region. Multiple myeloma (MM) is the second most common haematological cancer worldwide. Along with related diseases including monoclonal gammopathy of undetermined significance (MGUS), plasma cell leukaemia (PCL) and plasmacytoma, MM incidence is rising, yet it remains incurable and represents a significant disease burden. Clinical registries can provide important information on management and outcomes, and are vital platforms for clinical trials and other research. The Asia-Pacific Myeloma and Related Diseases Registry (APAC MRDR) was developed to monitor and explore variation in epidemiology, treatment regimens and their impact on clinical outcomes across this region. Here we describe the registry's design and development, initial data, progress and future plans. The APAC MRDR was established in 2018 as a multicentre collaboration across the Asia-Pacific, collecting prospective data on patients newly diagnosed with MM, MGUS, PCL and plasmacytoma in Korea, Singapore, Malaysia and Taiwan, with China recently joining. Development of the registry required a multidisciplinary team of clinicians, researchers, legal and information technology support, and financial resources, as well as local clinical context from key opinion leaders in the APAC region. Written informed consent is obtained and data are routinely collected throughout treatment by hospital staff. Data are stored securely, meeting all local privacy and ethics requirements. Data were collected from October 2018 to March 2024. Over 1700 patients from 24 hospitals have been enrolled onto the APAC MRDR to date, with the majority (86%) being newly diagnosed with MM. Bortezomib with an immunomodulatory drug was most frequently used in first-line MM therapy, and lenalidomide-based therapy was most common in second-line. Establishment and implementation challenges include regulatory and a range of operational issues. The APAC MRDR is providing 'real-world' data to participating sites, clinicians and policy-makers to explore factors influencing outcomes and survival, and to support high quality studies. It is already a valuable resource that will continue to grow and support research and clinical collaboration in MM and related diseases across the APAC region. Multiple myeloma (MM) is the second most common haematological cancer worldwide. Along with related diseases including monoclonal gammopathy of undetermined significance (MGUS), plasma cell leukaemia (PCL) and plasmacytoma, MM incidence is rising, yet it remains incurable and represents a significant disease burden. Clinical registries can provide important information on management and outcomes, and are vital platforms for clinical trials and other research. The Asia-Pacific Myeloma and Related Diseases Registry (APAC MRDR) was developed to monitor and explore variation in epidemiology, treatment regimens and their impact on clinical outcomes across this region. Here we describe the registry's design and development, initial data, progress and future plans.BACKGROUNDMultiple myeloma (MM) is the second most common haematological cancer worldwide. Along with related diseases including monoclonal gammopathy of undetermined significance (MGUS), plasma cell leukaemia (PCL) and plasmacytoma, MM incidence is rising, yet it remains incurable and represents a significant disease burden. Clinical registries can provide important information on management and outcomes, and are vital platforms for clinical trials and other research. The Asia-Pacific Myeloma and Related Diseases Registry (APAC MRDR) was developed to monitor and explore variation in epidemiology, treatment regimens and their impact on clinical outcomes across this region. Here we describe the registry's design and development, initial data, progress and future plans.The APAC MRDR was established in 2018 as a multicentre collaboration across the Asia-Pacific, collecting prospective data on patients newly diagnosed with MM, MGUS, PCL and plasmacytoma in Korea, Singapore, Malaysia and Taiwan, with China recently joining. Development of the registry required a multidisciplinary team of clinicians, researchers, legal and information technology support, and financial resources, as well as local clinical context from key opinion leaders in the APAC region. Written informed consent is obtained and data are routinely collected throughout treatment by hospital staff. Data are stored securely, meeting all local privacy and ethics requirements. Data were collected from October 2018 to March 2024.METHODSThe APAC MRDR was established in 2018 as a multicentre collaboration across the Asia-Pacific, collecting prospective data on patients newly diagnosed with MM, MGUS, PCL and plasmacytoma in Korea, Singapore, Malaysia and Taiwan, with China recently joining. Development of the registry required a multidisciplinary team of clinicians, researchers, legal and information technology support, and financial resources, as well as local clinical context from key opinion leaders in the APAC region. Written informed consent is obtained and data are routinely collected throughout treatment by hospital staff. Data are stored securely, meeting all local privacy and ethics requirements. Data were collected from October 2018 to March 2024.Over 1700 patients from 24 hospitals have been enrolled onto the APAC MRDR to date, with the majority (86%) being newly diagnosed with MM. Bortezomib with an immunomodulatory drug was most frequently used in first-line MM therapy, and lenalidomide-based therapy was most common in second-line. Establishment and implementation challenges include regulatory and a range of operational issues.RESULTSOver 1700 patients from 24 hospitals have been enrolled onto the APAC MRDR to date, with the majority (86%) being newly diagnosed with MM. Bortezomib with an immunomodulatory drug was most frequently used in first-line MM therapy, and lenalidomide-based therapy was most common in second-line. Establishment and implementation challenges include regulatory and a range of operational issues.The APAC MRDR is providing 'real-world' data to participating sites, clinicians and policy-makers to explore factors influencing outcomes and survival, and to support high quality studies. It is already a valuable resource that will continue to grow and support research and clinical collaboration in MM and related diseases across the APAC region.CONCLUSIONThe APAC MRDR is providing 'real-world' data to participating sites, clinicians and policy-makers to explore factors influencing outcomes and survival, and to support high quality studies. It is already a valuable resource that will continue to grow and support research and clinical collaboration in MM and related diseases across the APAC region. Background Multiple myeloma (MM) is the second most common haematological cancer worldwide. Along with related diseases including monoclonal gammopathy of undetermined significance (MGUS), plasma cell leukaemia (PCL) and plasmacytoma, MM incidence is rising, yet it remains incurable and represents a significant disease burden. Clinical registries can provide important information on management and outcomes, and are vital platforms for clinical trials and other research. The Asia-Pacific Myeloma and Related Diseases Registry (APAC MRDR) was developed to monitor and explore variation in epidemiology, treatment regimens and their impact on clinical outcomes across this region. Here we describe the registry's design and development, initial data, progress and future plans. Methods The APAC MRDR was established in 2018 as a multicentre collaboration across the Asia-Pacific, collecting prospective data on patients newly diagnosed with MM, MGUS, PCL and plasmacytoma in Korea, Singapore, Malaysia and Taiwan, with China recently joining. Development of the registry required a multidisciplinary team of clinicians, researchers, legal and information technology support, and financial resources, as well as local clinical context from key opinion leaders in the APAC region. Written informed consent is obtained and data are routinely collected throughout treatment by hospital staff. Data are stored securely, meeting all local privacy and ethics requirements. Data were collected from October 2018 to March 2024. Results Over 1700 patients from 24 hospitals have been enrolled onto the APAC MRDR to date, with the majority (86%) being newly diagnosed with MM. Bortezomib with an immunomodulatory drug was most frequently used in first-line MM therapy, and lenalidomide-based therapy was most common in second-line. Establishment and implementation challenges include regulatory and a range of operational issues. Conclusion The APAC MRDR is providing 'real-world' data to participating sites, clinicians and policy-makers to explore factors influencing outcomes and survival, and to support high quality studies. It is already a valuable resource that will continue to grow and support research and clinical collaboration in MM and related diseases across the APAC region. Keywords: Multiple myeloma, Clinical registry, Epidemiology, Real-world data Multiple myeloma (MM) is the second most common haematological cancer worldwide. Along with related diseases including monoclonal gammopathy of undetermined significance (MGUS), plasma cell leukaemia (PCL) and plasmacytoma, MM incidence is rising, yet it remains incurable and represents a significant disease burden. Clinical registries can provide important information on management and outcomes, and are vital platforms for clinical trials and other research. The Asia-Pacific Myeloma and Related Diseases Registry (APAC MRDR) was developed to monitor and explore variation in epidemiology, treatment regimens and their impact on clinical outcomes across this region. Here we describe the registry's design and development, initial data, progress and future plans. The APAC MRDR was established in 2018 as a multicentre collaboration across the Asia-Pacific, collecting prospective data on patients newly diagnosed with MM, MGUS, PCL and plasmacytoma in Korea, Singapore, Malaysia and Taiwan, with China recently joining. Development of the registry required a multidisciplinary team of clinicians, researchers, legal and information technology support, and financial resources, as well as local clinical context from key opinion leaders in the APAC region. Written informed consent is obtained and data are routinely collected throughout treatment by hospital staff. Data are stored securely, meeting all local privacy and ethics requirements. Data were collected from October 2018 to March 2024. Over 1700 patients from 24 hospitals have been enrolled onto the APAC MRDR to date, with the majority (86%) being newly diagnosed with MM. Bortezomib with an immunomodulatory drug was most frequently used in first-line MM therapy, and lenalidomide-based therapy was most common in second-line. Establishment and implementation challenges include regulatory and a range of operational issues. The APAC MRDR is providing 'real-world' data to participating sites, clinicians and policy-makers to explore factors influencing outcomes and survival, and to support high quality studies. It is already a valuable resource that will continue to grow and support research and clinical collaboration in MM and related diseases across the APAC region. BackgroundMultiple myeloma (MM) is the second most common haematological cancer worldwide. Along with related diseases including monoclonal gammopathy of undetermined significance (MGUS), plasma cell leukaemia (PCL) and plasmacytoma, MM incidence is rising, yet it remains incurable and represents a significant disease burden. Clinical registries can provide important information on management and outcomes, and are vital platforms for clinical trials and other research. The Asia–Pacific Myeloma and Related Diseases Registry (APAC MRDR) was developed to monitor and explore variation in epidemiology, treatment regimens and their impact on clinical outcomes across this region. Here we describe the registry’s design and development, initial data, progress and future plans.MethodsThe APAC MRDR was established in 2018 as a multicentre collaboration across the Asia–Pacific, collecting prospective data on patients newly diagnosed with MM, MGUS, PCL and plasmacytoma in Korea, Singapore, Malaysia and Taiwan, with China recently joining. Development of the registry required a multidisciplinary team of clinicians, researchers, legal and information technology support, and financial resources, as well as local clinical context from key opinion leaders in the APAC region. Written informed consent is obtained and data are routinely collected throughout treatment by hospital staff. Data are stored securely, meeting all local privacy and ethics requirements. Data were collected from October 2018 to March 2024.ResultsOver 1700 patients from 24 hospitals have been enrolled onto the APAC MRDR to date, with the majority (86%) being newly diagnosed with MM. Bortezomib with an immunomodulatory drug was most frequently used in first-line MM therapy, and lenalidomide-based therapy was most common in second-line. Establishment and implementation challenges include regulatory and a range of operational issues.ConclusionThe APAC MRDR is providing ‘real-world’ data to participating sites, clinicians and policy-makers to explore factors influencing outcomes and survival, and to support high quality studies. It is already a valuable resource that will continue to grow and support research and clinical collaboration in MM and related diseases across the APAC region. |
| ArticleNumber | 102 |
| Audience | Academic |
| Author | Moore, Elizabeth Chen, Pin-Yen Goh, Yeow Tee Waters, Neil A. Chng, Wee Joo Huang, Jeffrey Lu, Jin Yeh, Su-Peng Lee, Je Jung Wellard, Cameron McQuilten, Zoe K. Spencer, Andrew Chen, Wenming Wood, Erica M. Gan, Gin Gin Hou, Jian Kim, Kihyun Oliver, Laura Aoki, Naomi Min, Chang Ki |
| Author_xml | – sequence: 1 givenname: Naomi surname: Aoki fullname: Aoki, Naomi – sequence: 2 givenname: Pin-Yen surname: Chen fullname: Chen, Pin-Yen – sequence: 3 givenname: Wenming surname: Chen fullname: Chen, Wenming – sequence: 4 givenname: Wee Joo surname: Chng fullname: Chng, Wee Joo – sequence: 5 givenname: Gin Gin surname: Gan fullname: Gan, Gin Gin – sequence: 6 givenname: Yeow Tee surname: Goh fullname: Goh, Yeow Tee – sequence: 7 givenname: Jian surname: Hou fullname: Hou, Jian – sequence: 8 givenname: Jeffrey surname: Huang fullname: Huang, Jeffrey – sequence: 9 givenname: Kihyun surname: Kim fullname: Kim, Kihyun – sequence: 10 givenname: Je Jung surname: Lee fullname: Lee, Je Jung – sequence: 11 givenname: Jin surname: Lu fullname: Lu, Jin – sequence: 12 givenname: Zoe K. surname: McQuilten fullname: McQuilten, Zoe K. – sequence: 13 givenname: Chang Ki surname: Min fullname: Min, Chang Ki – sequence: 14 givenname: Elizabeth surname: Moore fullname: Moore, Elizabeth – sequence: 15 givenname: Laura surname: Oliver fullname: Oliver, Laura – sequence: 16 givenname: Neil A. surname: Waters fullname: Waters, Neil A. – sequence: 17 givenname: Cameron surname: Wellard fullname: Wellard, Cameron – sequence: 18 givenname: Erica M. surname: Wood fullname: Wood, Erica M. – sequence: 19 givenname: Su-Peng surname: Yeh fullname: Yeh, Su-Peng – sequence: 20 givenname: Andrew surname: Spencer fullname: Spencer, Andrew |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38698331$$D View this record in MEDLINE/PubMed |
| BookMark | eNptkslu2zAQhoUiRbO0L9BDQaCX5KCUmyiqN8PpEiBBA8M9E8PNoSGJrigffOs79Nqny5OUXpquIAgOZr75B0P8p8VRH3tXFC8JviREijeJUFnzEtPtpbQu8ZPihPCalJRKefRbfFycprTEmNSSiWfFMZOikYyRk-L7_N4hl0bQbUj3netHFD0C1K3bMaxah7qNa2MHyLShDwZaNLhFSOOwQaFHY26epAAPX7_dgQk-mF059m_R_N_S7UEKeotmroXRWXQVkoPkUk4cZM8nd5Mpup1dzS6eF089tMm9OLxnxef37-bTj-XNpw_X08lNaXjVjKUATZkV4AV3QBhrpPDU11pKR21VaS6sIMRorSmuDTHWcCx1hQVjghsM7Ky43uvaCEu1GkIHw0ZFCGqXiMNCwTAG0zpFLbUgiHGecl450litoeLCNJx6ClXWOt9rrYb4ZZ1_VnUhGde20Lu4TorhCjeswpRl9PVf6DKuhz5vuqU4abisq1_UAvL80Ps4DmC2ompSN4xkK_AmU5f_ofKxrgsm-8aHnP-j4dVh-Fp3zj5u_dMaGaB7wAwxpcH5R4RgtfWf2vtPZf-pnf8UZj8AH1jMbg |
| Cites_doi | 10.1371/journal.pone.0147381 10.2147/CLEP.S99463 10.1111/ejh.13707 10.1016/j.clml.2017.06.013 10.5694/j.1326-5377.2010.tb03499.x 10.1111/cas.16001 10.1182/blood-2022-164613 10.1007/s00277-019-03602-4 10.1001/jamaoncol.2018.2128 10.1186/s12874-016-0250-z 10.1016/S2152-2650(22)00548-1 10.2217/fon-2019-0013 10.5694/j.1326-5377.2011.tb03007.x 10.1182/blood-2007-10-116129 10.1016/j.clml.2019.09.625 10.1182/blood-2020-136896 10.3109/10428194.2016.1170828 10.1007/s00277-019-03858-w 10.1080/10428194.2020.1834098 10.1016/S1470-2045(13)70404-2 10.1016/j.clml.2014.12.002 10.1097/HS9.0000000000000045 10.5694/mja2.51443 |
| ContentType | Journal Article |
| Copyright | 2024. The Author(s). COPYRIGHT 2024 BioMed Central Ltd. 2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: 2024. The Author(s). – notice: COPYRIGHT 2024 BioMed Central Ltd. – notice: 2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| CorporateAuthor | the APAC MRDR Investigators APAC MRDR Investigators |
| CorporateAuthor_xml | – name: the APAC MRDR Investigators – name: APAC MRDR Investigators |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU COVID DWQXO FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI 7X8 DOA |
| DOI | 10.1186/s12874-024-02227-0 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Coronavirus Research Database ProQuest Central Korea Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection PML(ProQuest Medical Library) ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition MEDLINE - Academic DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition Coronavirus Research Database ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ: Directory of Open Access Journal (DOAJ) url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central Database Suite (ProQuest) url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1471-2288 |
| EndPage | 11 |
| ExternalDocumentID | oai_doaj_org_article_2d2da61cef2445e19dbba546c942f2a5 A793111849 38698331 10_1186_s12874_024_02227_0 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | Malaysia Singapore Asia Republic of Korea Taiwan South Korea China East Asia Uganda Australia Pacific Rim Canada United States--US Pacific region Europe |
| GeographicLocations_xml | – name: Singapore – name: Taiwan – name: Republic of Korea – name: Asia – name: Malaysia – name: South Korea – name: Australia – name: East Asia – name: China – name: Uganda – name: Pacific Rim – name: Canada – name: Pacific region – name: United States--US – name: Europe |
| GroupedDBID | --- 0R~ 23N 2WC 53G 5VS 6J9 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL AAYXX ABDBF ABUWG ACGFO ACGFS ACIHN ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK IAO IHR INH INR ITC KQ8 M1P M48 MK0 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS UKHRP W2D WOQ WOW XSB CGR CUY CVF ECM EIF NPM PJZUB PPXIY PMFND 3V. 7XB 8FK AZQEC COVID DWQXO K9. PKEHL PQEST PQUKI 7X8 PUEGO |
| ID | FETCH-LOGICAL-c459t-6ab23d6af64ea133986f2f7b88e2d55b46d611cbbb207c1cdc408b5063364c0a3 |
| IEDL.DBID | 7X7 |
| ISSN | 1471-2288 |
| IngestDate | Wed Aug 27 01:24:54 EDT 2025 Fri Jul 11 07:45:51 EDT 2025 Fri Jul 25 22:11:53 EDT 2025 Mon Aug 11 07:08:11 EDT 2025 Tue Jun 10 21:09:32 EDT 2025 Mon Jul 21 06:04:57 EDT 2025 Tue Jul 01 04:31:02 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Clinical registry Epidemiology Multiple myeloma Real-world data |
| Language | English |
| License | 2024. The Author(s). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c459t-6ab23d6af64ea133986f2f7b88e2d55b46d611cbbb207c1cdc408b5063364c0a3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://www.proquest.com/docview/3054194875?pq-origsite=%requestingapplication% |
| PMID | 38698331 |
| PQID | 3054194875 |
| PQPubID | 42579 |
| PageCount | 11 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_2d2da61cef2445e19dbba546c942f2a5 proquest_miscellaneous_3050935023 proquest_journals_3054194875 gale_infotracmisc_A793111849 gale_infotracacademiconefile_A793111849 pubmed_primary_38698331 crossref_primary_10_1186_s12874_024_02227_0 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2024-05-02 |
| PublicationDateYYYYMMDD | 2024-05-02 |
| PublicationDate_xml | – month: 05 year: 2024 text: 2024-05-02 day: 02 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | BMC medical research methodology |
| PublicationTitleAlternate | BMC Med Res Methodol |
| PublicationYear | 2024 |
| Publisher | BioMed Central Ltd BioMed Central BMC |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
| References | SM Evans (2227_CR10) 2011; 194 RM Rifkin (2227_CR17) 2015; 15 E Willenbacher (2227_CR19) 2016; 11 K Bergin (2227_CR13) 2016; 16 2227_CR12 L Brozova (2227_CR15) 2017; 30 J Ng (2227_CR30) 2022; 22 LJ Costa (2227_CR4) 2016; 57 A Chari (2227_CR6) 2020; 20 CH Blimark (2227_CR14) 2022; 108 SK Kumar (2227_CR2) 2008; 111 AJ Cowan (2227_CR1) 2018; 4 JJ Shah (2227_CR5) 2017; 17 2227_CR20 CH Tang (2227_CR3) 2020; 99 D Tan (2227_CR8) 2013; 14 2227_CR25 2227_CR27 2227_CR21 2227_CR22 VTM Hungria (2227_CR7) 2019; 98 2227_CR24 SGR Verelst (2227_CR18) 2018; 2 C Costello (2227_CR23) 2019; 15 S Ahern (2227_CR9) 2022; 216 JJ McNeil (2227_CR11) 2010; 192 P Gimsing (2227_CR16) 2016; 8 K Huynh (2227_CR29) 2020; 136 C Sun (2227_CR26) 2021; 62 M Alomran (2227_CR28) 2022; 140 |
| References_xml | – volume: 11 issue: 3 year: 2016 ident: 2227_CR19 publication-title: PLoS ONE doi: 10.1371/journal.pone.0147381 – volume: 8 start-page: 583 year: 2016 ident: 2227_CR16 publication-title: Clin Epidemiol doi: 10.2147/CLEP.S99463 – ident: 2227_CR27 – ident: 2227_CR21 – volume: 108 start-page: 99 issue: 2 year: 2022 ident: 2227_CR14 publication-title: Eur J Haematol doi: 10.1111/ejh.13707 – volume: 17 start-page: 575 issue: 9 year: 2017 ident: 2227_CR5 publication-title: Clin Lymphoma Myeloma Leuk doi: 10.1016/j.clml.2017.06.013 – volume: 192 start-page: 244 issue: 5 year: 2010 ident: 2227_CR11 publication-title: Med J Aust doi: 10.5694/j.1326-5377.2010.tb03499.x – ident: 2227_CR25 doi: 10.1111/cas.16001 – volume: 140 start-page: 10075 issue: Supplement 1 year: 2022 ident: 2227_CR28 publication-title: Blood doi: 10.1182/blood-2022-164613 – volume: 98 start-page: 941 issue: 4 year: 2019 ident: 2227_CR7 publication-title: Ann Hematol doi: 10.1007/s00277-019-03602-4 – volume: 4 start-page: 1221 issue: 9 year: 2018 ident: 2227_CR1 publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2018.2128 – volume: 16 start-page: 151 issue: 1 year: 2016 ident: 2227_CR13 publication-title: BMC Med Res Methodol doi: 10.1186/s12874-016-0250-z – volume: 22 start-page: S155 issue: Supplement 1 year: 2022 ident: 2227_CR30 publication-title: Myeloma & Leukemia doi: 10.1016/S2152-2650(22)00548-1 – volume: 15 start-page: 1411 issue: 13 year: 2019 ident: 2227_CR23 publication-title: Future Oncol doi: 10.2217/fon-2019-0013 – ident: 2227_CR12 – volume: 194 start-page: 360 issue: 7 year: 2011 ident: 2227_CR10 publication-title: Med J Aust doi: 10.5694/j.1326-5377.2011.tb03007.x – volume: 111 start-page: 2516 issue: 5 year: 2008 ident: 2227_CR2 publication-title: Blood doi: 10.1182/blood-2007-10-116129 – volume: 20 start-page: 8 issue: 1 year: 2020 ident: 2227_CR6 publication-title: Clin Lymphoma Myeloma Leuk doi: 10.1016/j.clml.2019.09.625 – volume: 136 start-page: 30 issue: Supplement 1 year: 2020 ident: 2227_CR29 publication-title: Blood doi: 10.1182/blood-2020-136896 – volume: 57 start-page: 2827 issue: 12 year: 2016 ident: 2227_CR4 publication-title: Leuk Lymphoma doi: 10.3109/10428194.2016.1170828 – ident: 2227_CR22 – ident: 2227_CR20 – volume: 99 start-page: 321 issue: 2 year: 2020 ident: 2227_CR3 publication-title: Ann Hematol doi: 10.1007/s00277-019-03858-w – ident: 2227_CR24 – volume: 30 start-page: 43 issue: Supplementum2 year: 2017 ident: 2227_CR15 publication-title: Data Collection and Visualisation Klin Onkol – volume: 62 start-page: 731 issue: 3 year: 2021 ident: 2227_CR26 publication-title: Leuk Lymphoma doi: 10.1080/10428194.2020.1834098 – volume: 14 start-page: e571 issue: 12 year: 2013 ident: 2227_CR8 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(13)70404-2 – volume: 15 start-page: 368 issue: 6 year: 2015 ident: 2227_CR17 publication-title: Clin Lymphoma Myeloma Leuk doi: 10.1016/j.clml.2014.12.002 – volume: 2 issue: 4 year: 2018 ident: 2227_CR18 publication-title: HemaSphere doi: 10.1097/HS9.0000000000000045 – volume: 216 start-page: 273 issue: 6 year: 2022 ident: 2227_CR9 publication-title: Med J Aust doi: 10.5694/mja2.51443 |
| SSID | ssj0017836 |
| Score | 2.3970346 |
| Snippet | Multiple myeloma (MM) is the second most common haematological cancer worldwide. Along with related diseases including monoclonal gammopathy of undetermined... Background Multiple myeloma (MM) is the second most common haematological cancer worldwide. Along with related diseases including monoclonal gammopathy of... BackgroundMultiple myeloma (MM) is the second most common haematological cancer worldwide. Along with related diseases including monoclonal gammopathy of... Abstract Background Multiple myeloma (MM) is the second most common haematological cancer worldwide. Along with related diseases including monoclonal... |
| SourceID | doaj proquest gale pubmed crossref |
| SourceType | Open Website Aggregation Database Index Database |
| StartPage | 102 |
| SubjectTerms | Asia - epidemiology Blood cancer Care and treatment Clinical medicine Clinical registry Clinical trials Consent Data collection Diagnosis Epidemiology Female Health care access Hospitals Humans Immunotherapy Inhibitor drugs Leukemia Lymphomas Malaysia - epidemiology Male Medical research Medicine, Experimental Middle Aged Multiple myeloma Multiple Myeloma - diagnosis Multiple Myeloma - epidemiology Multiple Myeloma - therapy Patient outcomes Patients Privacy Prospective Studies Quality of life Real-world data Registries (in medicine) Registries - statistics & numerical data Republic of Korea - epidemiology Services Singapore - epidemiology Taiwan - epidemiology Targeted cancer therapy |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrR1NaxUxMEgPxYto_VqtJYKgIks32Ww26W1tLUV4IqWF3kK-Fgp2V_peD978D179df4SZ7LZh88evHjNZEM2M5OZyXwR8oo51Ufd8zKCLluKFgxWxVK8g4hCOKErh-8di0_y5Fx8vGgu_mj1hTFhU3ng6eD2eeDBSuZjD4KoiUwH52wjpNeC99ym6qUg82ZjKvsPMDdhTpFRcn_JsKx7CfKoTMmfZbUhhlK1_tt38l-aZpI4x_fJvawq0m7a4gNyJw47ZHuRneEPyU9AMYUFbHpIwlc-OvbU0jlGkF59i1_GK0vn7EeKXRiwuRu9HCgofrRbXtpf33_kwLwEHocDenYbtMhL2SHQFD8XAz2afDtLGMjLvuk-d4d0cXp0-vYROT_-cHZ4UuZmC6UXjV6V0jpeB2l7KaIFw1Ur2fO-dUpFHprGCRkkY945x6vWMx-8qJRrQMOppfCVrR-TrWEc4lNCMQdRRxU1i1qI4MEkiqDmtTK0PaubUJB389mbr1NNDZNsESXNhCkDmDIJU6YqyHtEz3om1sNOA0AlJlOJ-ReVFOQ1Itcg166urbc5-QA2jPWvTAfXFNz6SuiC7G7MBG7zm-CZPEzm9qWBO1MwjaZfQV6uwfglRrANcbxJc9DnDCpSQZ5MZLX-pVpJreqaPfsfv_qc3OWJ0DHzfpdsra5v4gtQnFZuL_HIb7oxFHI priority: 102 providerName: Directory of Open Access Journals – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1baxUxEA6lgvgi3l1bJYKgIqubbDabCCJraynCipQe6FvIbaXQ7tpzTsG--R989df5S5xks0eOLb7mxm5mJvNNMheEnhEjOi87mnvAsjmrwWAVJPo7MM-YYbIw4b6j_cz3Z-zTUXW0gaZyR2kDF1eadqGe1Gx-8vr72cV7EPh3UeAFf7MgIWl7Dtomj6GdOZjw10Az1UFQW_b3VSFELEyBM1fOW1NOMYf_5ZP6H_wZ9dDeLXQzAUjcjBS_jTZ8fwddb9MT-V30CwiPYQEdr5fC3R8eOqzx5DmITy_8yXCq8RQTiUNthlDyDR_3GOAgbhbH-vePn8ldL3YP_Vt8eLmrTUvp3uHoVecd3h1ffBbQkJZ90XxpdnB7sHvw8h6a7X083NnPUwmG3LJKLnOuDS0d1x1nXoM5KwXvaFcbITx1VWUYd5wQa4yhRW2JdZYVwlSAe0rObKHL-2izH3r_EOEQmSi98JJ4yZizYCh5AH81d3VHyspl6NW09-rbmGlDRQtFcDVSSgGlVKSUKjL0IZBnNTJkyY4Nw_yrSkKnqKNOc2J9ByCm8kQ6Y3TFuJWMdlRXGXoeiKsCdy3n2uoUkgAfHLJiqQYOL9AFgskMba-NBBm0690Te6iJhRWcpIzIYBBm6OmqO8wMfm29H87jmPASDcApQw9Gtlr9Uim4FGVJHv1_8S10g0YWDpH222hzOT_3jwEoLc2TyP1_AIYoDlg priority: 102 providerName: Scholars Portal |
| Title | The establishment of a multiple myeloma clinical registry in the Asia–Pacific region: The Asia–Pacific Myeloma and Related Diseases Registry (APAC MRDR) |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/38698331 https://www.proquest.com/docview/3054194875 https://www.proquest.com/docview/3050935023 https://doaj.org/article/2d2da61cef2445e19dbba546c942f2a5 |
| Volume | 24 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LixQxEA66C-JFfNu6DhEEFWm2051OJ15kZh8swizLsAuLl5BXy4Lbvc7MHrz5H7z66_wlVmXSI-OClxySdOjuqlS-qtSDkNfMyjaotswDYNmcN6CwShb9HXjg3HJVWLR3TI_F0Rn_dF6fJ4PbIrlVDjIxCmrfO7SR7wJfclC4AV5_vPqWY9UovF1NJTRuk21MXYYuXc35WuFiGKEwBMpIsbtgmNw9h1MpjyGgebFxGMWc_Tcl8z94M547h_fJvQQY6XhF4QfkVugekjvTdCX-iPwCQlNYwERzEtr6aN9SQwdPQXr5PXztLw0dYiAp1mLAEm_0oqMA_-h4cWF-__iZ3PPicN99oKc3h6ZpKdN5Gr3ogqf7qxueBXSkZd-OT8Z7dDrbn717TM4OD073jvJUciF3vFbLXBhbVl6YVvBgQH1VUrRl21gpQ-nr2nLhBWPOWlsWjWPOO15IWwPOqQR3hamekK2u78IzQjESUQUZFAuKc--AcgHAXiN807Kq9hl5P_x7fbXKrKGjRiKFXlFKA6V0pJQuMjJB8qxnYlbs2NHPv-i0yXTpS28Ec6EF0FIHpry1pubCKV62pakz8gaJq3HvLufGmRSCAC-MWbD0GIQVyH7JVUZ2NmbCnnObwwN76LTnF_ovh2bk1XoYn0Q_ti7013EO3jwDUMrI0xVbrT-pkkLJqmLP_7_4C3K3jCyMkfU7ZGs5vw4vARgt7Shy_4hsTw6OT2ajaF6AdsoltLPJ5z_J6w-x |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3dbtMwFLZGJwE3iH8CA4wEAjRFSxzHtZEQ6tZNHVurqeqk3Rn_ZZq0JaPthHbHO3DLM_BQPAnHTlJUJnG329g9Snr-vuNzjg9Cr1PNCycKEjvAsjHtQsDK01DvQB2lmopE-_OO4YgNDunno_xoBf1qe2F8WWVrE4OhtpXxZ-QbIJcUAm6A15_Ov8Z-apTPrrYjNGqx2HOX3yBkm33c7QN_3xCysz3ZGsTNVIHY0FzMY6Y0ySxTBaNOQYQmOCtI0dWcO2LzXFNmWZoarTVJuiY11tCE6xxcecaoSVQGdG-gVZpBKNNBq5vbo4PxIm_heyLa1hzONmapv04-Bj8Yh6bTOFlyf2FKwFVf8A_CDZ5u5y6600BU3Ktl6h5aceV9dHPYJOEfoJ8gWhgIqHCA5U8XcVVghdvaRHx26U6rM4Xbrkvspz_4oXL4pMQAOHFvdqJ-f__RFASG5ar8gCdXl4YNKVVaHOr2nMX9Oqc0gwcN2Xe9g94WHo774_cP0eG1sOMR6pRV6Z4g7HsfheNOpE5Qag3IigN42WW2W6RZbiO03v738ry-y0OGGIgzWXNKAqdk4JRMIrTp2bPY6e_hDg-q6bFs1FoSS6xiqXEFwKTcpcJqrXLKjKCkICqP0FvPXOmtxXyqjGqaHuCF_b1bsgfmEbwNpyJCa0s7QcvN8nIrHrKxMjP5Vyci9Gqx7H_pK-dKV12EPT7XDdAsQo9rsVp8UsaZ4FmWPv0_8Zfo1mAy3Jf7u6O9Z-g2CeLs-_rXUGc-vXDPAZbN9YtGFzD6ct3q9wc3bUl8 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+establishment+of+a+multiple+myeloma+clinical+registry+in+the+Asia%E2%80%93Pacific+region%3A+The+Asia%E2%80%93Pacific+Myeloma+and+Related+Diseases+Registry+%28APAC+MRDR%29&rft.jtitle=BMC+medical+research+methodology&rft.au=Aoki%2C+Naomi&rft.au=Pin-Yen%2C+Chen&rft.au=Chen%2C+Wenming&rft.au=Chng%2C+Wee+Joo&rft.date=2024-05-02&rft.pub=BioMed+Central&rft.eissn=1471-2288&rft.volume=24&rft.spage=1&rft_id=info:doi/10.1186%2Fs12874-024-02227-0 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2288&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2288&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2288&client=summon |